title: Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies.
abstract: OBJECTIVE
  To assess somatoform disorder (SFMD) prevalence and impact in Parkinson disease (PD) and dementia with Lewy bodies (DLB).
  
  
  METHODS
  SFMD were assessed by direct observation of symptoms in the year coincident (+/-6 months) with definite diagnosis of PD, DLB, Alzheimer disease, multiple system atrophy, progressive supranuclear palsy, or frontotemporal dementia, and by interviews with patients, caregivers, and general practitioners, and reviews of prior hospital admissions, in a cohort of 942 patients with neurodegenerative disorders. Matched groups of patients with PD and patients with DLB without vs with SFMD were selected for comparisons and followed up over 4 years.
  
  
  RESULTS
  The frequency of SFMD was higher in DLB (15 patients, 12%) and PD (29 patients, 7%) than in other neurodegenerative diseases (0%-3%). SFMD consisted of conversion motor or sensory disorders, often accompanied by delusional thought content; in one patient catatonic symptoms were observed concomitantly with PD diagnosis. Evidence of SFMD symptoms, preceding diagnosis by 6 months-10 years, was obtained in 28 patients with PD and all patients with DLB. A total of 22 patients with PD and all patients with DLB could be followed for 4 years. SFMD symptoms recurred during follow-up, with catatonic signs developing in 9 patients with PD and 8 patients with DLB. Most baseline demographic and clinical features did not differ between subjects with or without SFMD. Decline of cognitive function was greater in PD-SFMD patients than in those without SFMD (p < 0.01); it was comparable to that observed in DLB.
  
  
  CONCLUSIONS
  The frequency of somatoform disorder (SFMD) (with catatonic signs) in Parkinson disease and dementia with Lewy bodies suggests that SFMD are part of the spectrum of Lewy body diseases.
authors.affiliation: Department of Neurology, University G. d'Annunzio of Chieti-Pescara, Italy. onofrj@unich.it
authors.forename: Marco
authors.initials: M
authors.lastname: Onofrj
authors.forename: Laura
authors.initials: L
authors.lastname: Bonanni
authors.forename: Lamberto
authors.initials: L
authors.lastname: Manzoli
authors.forename: Astrid
authors.initials: A
authors.lastname: Thomas
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000175:diagnosis / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000175:diagnosis / Q000453:epidemiology*; D015995:Prevalence; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D013001:Somatoform Disorders / Q000175:diagnosis / Q000453:epidemiology*